GlassScriptPhysician profile
Rachel Vantries
NPI 1700537461
$3,149.64
in general payments reported to CMS, 2019-2025
25 companies · $1,212 in 2025
The $1,212 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $99.70 · 2023: $267 · 2024: $1,571 · 2025: $1,212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,049.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $706.20 | 2024-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $530.03 | 2022-2025 | |
| Tris Pharma INC | $348.77 | 2023-2025 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $174.02 | 2024 | Spravato |
| Corium, LLC | $168.00 | 2023-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $157.81 | 2024-2025 | Caplyta |
| Almatica Pharma LLC | $144.32 | 2023-2025 | Loreev Xr, Teriparatide |
| Axsome Therapeutics, INC. | $139.75 | 2025 | Auvelity, Sunosi |
| Supernus Pharmaceuticals, INC. | $113.36 | 2024 | Qelbree |
| Hologic Sales and Service, LLC | $98.01 | 2022-2024 | Acessa Provu System, Novasure, Myosure Tissue Removal Device |
| Otsuka America Pharmaceutical, INC. | $77.78 | 2024-2025 | Rexulti |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $68.81 | 2024-2025 | Rejoyn |
| Collegium Pharmaceutical, INC. | $64.02 | 2025 | Jornay Pm |
| Alkermes, INC. | $60.25 | 2025 | Lybalvi, Aristada |
| Ironshore Pharmaceuticals INC. | $52.28 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $43.74 | 2025 | Relexxii |
| Mayne Pharma Commercial LLC | $37.48 | 2023 | |
| Exeltis, USA INC. | $32.71 | 2022-2023 | Slynd |
| Biogen, INC. | $24.49 | 2024 | |
| Neos Therapeutics, LP | $21.55 | 2025 | Adzenys Xr-Odt |
| Coopersurgical, INC. | $20.42 | 2022 | |
| Neurocrine Biosciences, INC. | $18.33 | 2024 | Ingrezza |
| Galderma Laboratories, L.P. | $17.77 | 2023 | |
| Axonics, INC. | $15.58 | 2023 | Axonics |
| Organon LLC | $14.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Vantries listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.